BamSEC and AlphaSense Join Forces
Learn More

Ionis Pharmaceuticals Inc. – Material Contracts

NASDAQ: IONS    
Share price (3/17/26): $72.33    
Market cap (3/17/26): $11.9 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K/A 16 pages Terms of Advisory Services Agreement
12/34/56
EX-10.7
from 10-Q 2 pages Amendment No. 1
12/34/56
EX-10.6
from 10-Q 141 pages Strategic Collaboration Agreement Between ISIS Pharmaceuticals, Inc., and Astrazeneca Ab
12/34/56
EX-10.5
from 10-Q 2 pages Amendment No. 4
12/34/56
EX-10.4
from 10-Q 5 pages Amendment No.3
12/34/56
EX-10.3
from 10-Q 2 pages Amendment No.2
12/34/56
EX-10.2
from 10-Q 12 pages Amendment #1 to Collaboration, License and Development Agreement
12/34/56
EX-10.1
from 10-Q 125 pages Collaboration, License and Development Agreement Between ISIS Pharmaceuticals, Inc., and Astrazeneca Ab Collaboration, License and Development Agreement
12/34/56
EX-10.2
from 10-Q 93 pages License Agreement Between Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd. Dated March 10, 2025
12/34/56
EX-10.1
from 10-Q 2 pages Third Amended Non-Employee Director Compensation Policy as of March 6, 2025
12/34/56
EX-10.58
from 10-K 36 pages Certain Portions of This Exhibit, Marked by [***], Have Been Excluded Because They Are Both Not Material and Are the Type That the Registrant Treats as Private or Confidential. Amendment No. 4
12/34/56
EX-10.2
from 10-Q 122 pages Certain Portions of This Exhibit, Marked by [***], Have Been Excluded Because They Are Both Not Material and Are the Type That the Registrant Treats as Private or Confidential. Amended and Restated License Agreement by and Between Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. Dated June 18, 2024
12/34/56
EX-10.1
from 10-Q 6 pages Second Amendment to Amended and Restated Lease
12/34/56
EX-10.1
from 10-Q 9 pages Terms of Advisory Agreement
12/34/56
EX-10.80
from 10-K 109 pages License Agreement by and Between Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. Dated December 15, 2023
12/34/56
EX-10.25
from 10-K 6 pages First Amendment to Amended and Restated Lease
12/34/56
EX-10.3
from 10-K 7 pages Indemnity Agreement
12/34/56
EX-10.3
from 10-Q 97 pages Research, Development, and License Agreement Among Ionis Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc
12/34/56
EX-10.2
from 10-Q 149 pages Amended and Restated Lease Agreement Dated as of August 21, 2023 Between Lots 21 & 22 Owner (De) LLC a Delaware Limited Liability Company as Landlord and Ionis Pharmaceuticals, Inc., a Delaware Corporation as Tenant Basic Lease Information
12/34/56
EX-10.1
from 10-Q 95 pages Collaboration and License Agreement Between Ionis Pharmaceuticals, Inc. and Novartis Pharma AG Collaboration and License Agreement
12/34/56